Aventis Pharma S.a.

Aventis Pharmaceuticals Inc.

Sanofi

Chantal Carrez

Francois Clerc

Michael L Edwards

Frank Halley

Andrew David Morley

Herve Bouchard

Patrick Mailliet

Dominique Damour

Conception Nemecek

Tahir Nadeem Majid

Paul Joseph Cox

Brian L Pedgrift

Shelley Amendola

Dorothea Kominos

Didier Benard

Justine Yeun Quai Lai

Luc Bertin

Olivier Houille

Daniel N A Bezard

Eric Bacque

Jean-Marie Ruxer

Ercole Rao

Christian Lange

Fabienne Thompson

Thierry Guyon

Charles J Gardner

Timothy A Gillespy

Christopher D Edlin

Christian Beil

Cendrine Lemoine

Stephanie Deprets

Hervé Minoux

Jochen Beninga

Fabienne Pilorge

Odile Angouillant-Boniface

Katja Kroll

Wulf-Dirk Leuschner

Peter Wonerow

Stéphanie Deprets

Marion Schneider

Hélène Goulaouic

Francois Hamy

Jana Albrecht

François Vallee

Cédric Barriere

Stéphane Guerif

Thierry Gouyon

Isabelle Depaty

Manfred Roesner

Stephanie D Deprets

Marie-Cécile Wetzel

The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.

Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123

This invention relates to isoindole derivates of Formula I to pharmaceutical compositions comprising such derivatives, and to methods of treatment comprising administering of such derivatives.

Isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as inhibitors of chaperone protein Hsp90 activities

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

This invention relates to derivatives of 4-(benzimidazol-2-yl)fluorene and 4-(azabenzimidazol-2-yl)fluorene, to pharmaceutical compositions comprising such derivatives, and to methods of treatment of disorders related to Hsp90 protein activity, comprising administering such derivatives.

Fluorene derivatives, composition containing said derivatives and the use thereof

The present invention discloses and claims benzimidazole compounds of formula (I):in which A is aryl or heteroaryl; Ris selected from optionally substituted alkyl, alkoxy, aryl or heteroaryl, NH-lower alkyl or NH-cycloalkyl, or halogen, NH; 1-imidazolyl or SOMe; Ris selected from optionally substituted &#x2014;CO-alkyl, &#x2014;CO-cycloalkyl, &#x2014;CO-aralkyl, &#x2014;CO-aryl, &#x2014;CO-alkoxy, aryl or aralkyl, or &#x2014;CO-amino, CO&#x2014;NHRor CO&#x2014;RRwherein Rand Rare selecteded independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl, alkylheteroalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms; a pharmaceutically acceptable salt or a prodrug thereof; the use of compounds of formula (I) for the treatment of cancer, and pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents.

Substituted benzimidazole compounds and their use for the treatment of cancer

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

Growing community of inventors

Thiais, France

Chantal Carrez